“…Subsequently, increased levels of p-eIF2α were found in the cortex and hippocampus of AD patients and in AD mouse models (Chang et al, 2002b; Devi and Ohno, 2013; Hoozemans et al, 2009; Kim et al, 2007; Lewerenz and Maher, 2009; Ma et al, 2013; Mouton-Liger et al, 2012; O’Connor et al, 2008; Page et al, 2006; Stutzbach et al, 2013; Unterberger et al, 2006). In addition to AD, p-eIF2α levels are elevated in the brain or spinal cord of patients and mice with prion disease (Unterberger et al, 2006), amyotrophic lateral sclerosis (ALS; Ilieva et al, 2007), Parkinson’s disease (PD; Hoozemans et al, 2007, 2012), Huntington’s disease (HD; Leitman et al, 2014), and various tauopathies (Köhler et al, 2014; Nijholt et al, 2012; Radford et al, 2015; Stutzbach et al, 2013; Unterberger et al, 2006). …”